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Abstract
Rising rates of adiposity in the young pose one of the greatest threats to future
population burden of cardiovascular disease. Understanding the contribution of
genetic and early-life influences to adiposity profiles in young adulthood – when
the first signs of subclinical cardiovascular disease commonly appear – are vital
if effective lifetime prevention strategies are to be developed. This data note
documents the extensive range of genotypic and phenotypic data available
from a London-based sub-study of the long-running Avon Longitudinal Study of
Parents and Children (ALSPAC)—the ‘ALSPAC in London’ Study—in which
extensive adipose and cardiovascular phenotyping was carried out in
participants recruited based on a genetic predisposition to obesity.
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Introduction
The recent worldwide increase in population adiposity threatens 
to reverse achieved reductions in cardiovascular morbidity 
and mortality. The fastest rises in adiposity rates have been in 
children, teenagers and young adults and therefore represent 
one of the major growing threats to worldwide public health. 
The Avon Longitudinal Study of Parents and Children (ALSPAC) 
is a longitudinal birth cohort that recruited pregnant women 
living near Bristol, UK with an estimated delivery date between 
1991 and 1992. The study includes extensive phenotypic, genetic, 
epigenetic and metabolomic data on the mothers, fathers and 
children from questionnaires, clinics and samples, and follow 
up is ongoing. Using a novel ‘recall-by-genotype’ study design to 
identify individuals with genetically predicted variation in body 
mass index (BMI)1, the ‘ALSPAC in London’ study aimed to 
examine the impact of adiposity on metabolic, inflammatory 
and autonomic disturbances, as well as their relationship to 
cardiovascular (CV) structure and function, with genetically-
directed deep phenotyping.
Methods
ALSPAC recruited 14,541 pregnant women resident in Avon, 
UK (former county covering Bristol and the surrounding areas 
in the South West UK) with expected dates of delivery 
1st April 1991 to 31st December 19922,3. The initial number of 
pregnancies for which the mother enrolled in the ALSPAC study 
and had either returned at least one questionnaire or attended a 
“Children in Focus” clinic by 19/07/99 is 14,541. Of these 
initial pregnancies, there were a total of 14,676 fetuses, result-
ing in 14,062 live births and 13,988 children who were alive at 
1 year of age. When the oldest children were approximately 
7 years of age, an attempt was made to bolster the initial 
sample with eligible cases who had failed to join the study 
originally. As a result, when considering variables collected 
from the age of seven onwards (and potentially abstracted 
from obstetric notes) there are data available for more than 
the 14,541 pregnancies mentioned above.
The number of new pregnancies not in the initial sample 
(known as Phase I enrolment) that are currently represented 
in the study and reflecting enrolment status at the age of 18 is 
706 (452 and 254 recruited during Phases II and III respec-
tively), resulting in an additional 713 children being enrolled. The 
phases of enrolment are described in more detail in the cohort 
profile paper2,3.
The total sample size for analyses using any data collected after 
the age of seven is therefore 15,247 pregnancies, resulting in 
15,458 foetuses. Of this total sample of 15,458 foetuses, 
14,775 were live births and 14,701 were alive at 1 year of age2,3.
The data included in this resource were collected from 
436 young adults (mean age 21 ± 1 years) recalled for exten-
sive adipose and cardiometabolic phenotyping between 2011 
and 2015. Of these, 419 were recruited based on a genetic 
propensity for high or low BMI, with the other 17 comprising 
patients recruited prior to the decision to employ a recall-by- 
genotype study design.
Dataset 1 – genetic risk groups
Original beta-coefficients for the genome-wide genetic risk 
score (GRS) assembly were obtained directly from the 
genome-wide association study (GWAS) of BMI, conducted in 
2010 by Speliotes et al.4, with the ALSPAC data removed 
from the release. All alleles were aligned such that the refer-
ence allele matched the BMI-increasing direction reported in the 
GWAS and plink (--score) was used to derive a score for each 
participant (N=8,350). After removing heterozygous haploid 
genotypes (N=46,067), direct genotypes were available for 
500,527 SNPs, of which 472,208 mapped to SNPs that 
overlapped with the Speliotes et al.4 GWAS results and 470,667 
mapped to alleles. The ALSPAC genetic dataset used was 
the best available data at the time of the RbG study design (2012) 
and was subsequently used in several papers5,6. The number 
of participants invited and recruited to the RbG study was 
orchestrated based on an a priori power calculation taking into 
account the predicted explained variation in BMI by the genome-
wide GRS and its effect size on an example cardiovascular 
phenotype (SBP). Specifically, using the observed associa-
tion between SBP and BMI at age 17, we calculated that we 
would require 450 participants in our RbG to be able to detect a 
difference of 3 mmHg (a difference that in young adulthood has 
clinically meaningful association with future cardiovascular 
disease (CVD)7 with 80% power and a two-sided p-value 
threshold of 0.05 and assuming an approximate 3.3kg/m2 unit 
difference in BMI between recalled groups. Participants 
were then recruited according to their appearance in nine 
sampling groups, from the most extreme to the least, to maximise 
power and difference in BMI. These samples were as 
follows: 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27% from 
the lower tail of the genome-wide GRS distribution and 97%, 
94%, 91%, 88%, 85%, 82%, 79%, 76%, 73% from the upper 
tail of the genome-wide GRS distribution The GRS was 
computed for 4,602 individuals in total within these sampling 
groups. Of those who were invited to the study (N=2,071), 
419 individuals attended from across the entire distribution of 
sampling groups and had both full genetic and BMI data.
Dataset 2 – participant characteristics
Height was measured in metres using a stadiometer (SECA 
213, Birmingham, UK) and weight in kilograms using electronic 
weighing scales (Marsden M-110, Rotherham, UK). BMI was 
calculated as weight (kg) / height (m)2. Waist circumference 
was measured in centimetres at the narrowest circumference of 
the abdomen (roughly level to the umbilicus) using a standard 
flexible tape measure. Hip circumference was measured in 
centimetres at the widest circumference of the hips/buttocks 
using a standard flexible tape measure. Sagittal abdominal diam-
eter was measured in centimetres as the distance between the small 
of the back and the top of the abdomen, with all measurements 
taken in the supine position with specialist metal callipers. 
Numerous other measures such as medical history, recent 
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Figure 1. Study flow diagram.
illnesses, smoking, alcohol consumption, physical activity and 
menstrual cycle were recorded via questionnaire, a copy of 
which is available as extended data8.
Dataset 3 – adipose phenotypes
Body fat volume and distribution was measured using a 1.5T 
magnetic resonance imaging (MRI) system (Avanto; Siemens 
Medical Solutions). A graphics processing unit (GPU) imple-
mentation of the T2-IDEAL algorithm was used to measure body 
fat content. This technique iteratively separated MR images into 
fat and water components, which could then be used to measure 
the proportion of fat in each 36x36x10 mm voxel. Data was 
acquired in a continuous stack of 10 mm thick slices from the 
neck to the knees. To prevent motion artefact, breath holding was 
used for the thorax and abdomen and cardiac gating for slices 
containing the heart. Fat quantification in the head, arms and 
below the knees was impractical due to the need for participant 
re-positioning or specialised coils. Due to their low fat content 
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these body parts were excluded using anatomical landmarks 
to ensure consistency between participants. The visceral com-
partment was manually separated from the fat image and the 
liver was excluded due to frequent artefacts at diaphragm 
level. Absolute volumes of fat were calculated for subcutaneous, 
visceral, liver, and pericardial deposits.
Dataset 4 – cardiovascular phenotypes
Carotid intima-media thickness. Common carotid artery 
intima-media thickness (cIMT) was measured using B-mode 
ultrasound images acquired in the ear-to-ear plane with the head 
rotated to 45° from the midpoint using a Zonare Z.OneUltra sys-
tem equipped with a L10-5 linear transducer (Zonare Medical 
Systems, CA, US). Images were recorded in Digital 2 Imaging 
and Communications in Medicine (DICOM) format as 10 second 
cine-loop files for offline analysis using Carotid Analyzer soft-
ware (Medical Imaging Applications, Coralville, IA). Left and 
right cIMT were taken to be the average of three end-diasto-
lic measurements located on the far-wall of a single segment of 
arterial wall 5–10 mm in length and 10 mm proximal to the 
bifurcation.
Pulse wave velocity. Pulse-wave velocity (PWV) was used to 
estimate arterial stiffness via applanation tonometry (Sphygmo-
Cor Vx, AtCor Medical, NSW, Australia). Two distinct indices 
of PWV were measured, using electrocardiogram (ECG)-gated 
pulse waves travelling between both carotid-radial and carotid- 
femoral sites. The participant was rested in a supine position and 
a handheld tonometer was placed over the left carotid artery in 
order to allow the recording of 10–12 clear and reproducible pres-
sure waveforms. The same tonometer was then used to measure 
a similar number of femoral arterial pulse waveforms in the 
inguinal crease at the top of the right leg, or radial arterial pulse 
waveforms in the right wrist. Carotid-radial transit distance 
was measured between the upper edge of the suprasternal notch 
and the radial pulse measurement site using a tape measure, 
whereas carotid-femoral transit distance was measured between 
carotid and femoral sites both directly and via the umbilicus. 
The device software calculated the mean transit time (in milli-
seconds) from the recorded pulse waveforms and carotid-femoral 
and carotid-radial PWV were calculated as the transit distance/ 
transit time.
Pulse wave analysis. Estimates of central blood pressure (BP) 
and indices of systemic arterial stiffness such as augmentation 
pressure (AP) and augmentation index (AIx) were assessed 
using pulse wave analysis (SphygmoCor Vx, AtCor Medical, NSW, 
Australia). This technique measures the arterial pressure wave-
form at the radial artery and applies a validated generalised trans-
fer function to provide the central pressure waveform. Participants 
lay supine on a couch in ambient conditions for at least 10 mins 
prior to the start of the assessment. Brachial BP was meas-
ured using a digital automated sphygmomanometer (Omron M6 
Comfort). With the participant’s wrist held steady, the tonometer 
probe was placed over the right radial artery at the level of the 
wrist and a recording of 10–12 pressure waveforms was saved to 
specialist software. Quality indices (average pulse height, pulse 
height variation, diastolic variation, and shape deviation) were 
assessed for each measurement to confirm they fell within 
acceptable limits (automatically calculated), otherwise the scan 
was repeated.
Autonomic function. Autonomic function was assessed using 
measures of baroreflex sensitivity (BRS) and heart rate vari-
ability (HRV). Participants lay supine on a couch in a darkened 
room in ambient conditions for at least 10 mins prior to the start 
of the assessment. Following this, a 3-lead ECG and 4-lead res-
piratory monitoring system were attached to the participant’s 
chest to measure heart rate and breathing cycle, while an inflat-
able infrared photoplethysmographic cuff (Portapres, FMS, 
Netherlands) was attached to the middle finger of the right hand 
and (following calibration) inflated in order to continuously and 
non-invasively measure BP. Participants remained at rest for 
20 mins while measurements were recorded by the software, 
with all signals fed to specialist software for the calculation of 
BRS and HRV. A stationary period of 5 min with less than 5% 
atrial/ventricular ectopic beats was chosen for the temporal QT 
interval variability analysis using a computer algorithm. The 
examiner defined a template QT interval for one beat from the 
beginning of the QRS complex to the end of T wave, includ-
ing all deflections that might relate to repolarization, including 
possible U waves. The algorithm found the QT intervals of all 
other beats by determining the stretch or compression in time 
of each beat that best matched the ST segment and the T wave 
of the template beat, whereas the QRS complex was ignored. 
RR interval mean and variance and QT interval mean and vari-
ance were derived from the respective time series. QTVI, which 
represents the log ratio between normalized QT and RR interval 
variability, was calculated according to the equation: QTVI = log10 
[(QTv ⁄QTm2)/(RRv/RRm2)], whereby a difference of 1 QTVI 
between two individuals implies a tenfold difference in temporal 
QT variability normalized to the QT interval, RR variance (HRV 
calculated in the time domain) and the RR interval. The squared 
coherence function was calculated from power spectra of the 
RR and QT interval time series and the cross-spectrum between 
these two series derived by fast Fourier Transform (Welch 
algorithm, five blocks, 50% overlap, Hanning window). The mean 
squared coherence was obtained by averaging the coherence 
function over the frequency band from 0 to 0.45 Hz. The coher-
ence provides a measurement of the degree of linear interaction 
between the RR and QT interval fluctuations as a function 
of the frequency of those fluctuations. For BRS calculations, 
registrations were recorded at a sampling frequency of 1000 
Hz and stored on a computer. The recordings were inspected 
offline for the removal of artefactual segments and sequences 
containing non-sinus beats. Ectopic beats were corrected by inter-
polation. The time series of systolic blood pressure (SBP) and 
RR interval from the entire period of recording (20 min) were 
scanned to identify baroreflex sequences, which were defined 
as three or more consecutive beats in which successive SBP 
and RR intervals concordantly increased or decreased, with the 
threshold set at 1.0 mmHg and 5.0 ms, respectively, and a shift 
of +1 between the BP pulse and the RR interval, resembling the 
classical criteria suggested by Bertinieri et al.9 (threshold val-
ues of 1.0 mmHg and 4.0 ms, respectively and shift 1). Linear 
regression was applied to each sequence and only those for 
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which the square of the correlation coefficient (r2) was greater 
than 0.85 were accepted for further analysis. The spontaneous 
BRS was calculated, reflecting the average regression slope for 
all the linear regressions. RR data were used to derive standard 
deviation of normal-to-normal RR intervals (SDNN) for 
time-domain HRV.
Ultra-high frequency ultrasound (UHFUS). In a randomly-
selected sub-sample of participants, images of individual 
intima and media thicknesses (IT and MT, respectively) were 
obtained in the carotid, radial and dorsal pedal arteries using an 
ultra-high resolution ultrasound system (UHFUS; Vevo 2100, 
Visualsonics) with attached 40 MHz and 50 MHz transducers. 
Right common carotid artery scans were obtained via UHFUS 
and imaged longitudinally 1–2 cm proximal to the carotid bifur-
cation. Images were focused on the posterior (far) wall of the 
artery and the zoom function was used to magnify the area. Right 
radial artery scans were collected in the same way at a location 
1–2 cm proximal to the skin fold separating the palma manus 
from the region antebrachii anterior. Right dorsal paedal scans 
were measured above the proximal first metatarsal bone in the 
foot. Images were recorded in DICOM format as cine loops 
for off-line analysis. IT echo was assessed offline and its total 
thickness measured with callipers within a standardised 
(8mm×8 mm) higher resolution zoom. The image was acquired, 
temporarily stored in the cine loop and consecutively zoomed 
when the measurements were done. The measurements of the 
IT were performed in systole of the vessel (determined by scroll-
ing through the cine loop to reach the arteries largest diameter). 
The MT was then calculated as the difference between IMT and 
IT (MT = IMT−IT). IMT was defined as the distance from the 
leading edge of the lumen–intima interface to the leading edge of 
the media–adventitia interface. Lumen diameter was defined by 
the distance between the leading edges of the intima–lumen 
interface of the near wall and the lumen–intima interface of the 
far wall.
Cardiovascular magnetic resonance imaging. Cardiovascular 
MRI was used to assess numerous measures of cardiovascu-
lar structure and function. All measures were made using a 
1.5T MR scanner (Avanto, Siemens Medical Solutions, Erlan-
gen, Germany). Endocardial borders of the left ventricle (LV) 
were traced manually on short axis stacks at end-diastole and 
end-systole to evaluate end-diastolic volume (EDV) and end- 
systolic volume (ESV). Stroke volume (SV) was obtained by 
subtracting ESV from EDV. Epicardial borders were traced in 
end-diastole to calculate an epicardial volume. The EDV was 
subtracted from this volume, multiplied by assumed myocardial 
density to obtain left ventricular mass (LVM). Flow quantifica-
tion was performed through-plane in a cross-section of the ascend-
ing aorta as it passes the bifurcation of the pulmonary arteries 
using an ECG-gated spiral phase-contrast MRI sequence. This 
technique allows images to be acquired within a short breath-
hold (0.5 seconds) with a spatial resolution of 1.6 x 1.6 mm and 
a temporal resolution of 30 ms. All images were processed using 
in-house plug-ins for the Open source software OsiriX (OsiriX 
Foundation, Geneva, Switzerland). Flow images were manually 
segmented (using the modulus images) and SV (ml) was measured 
and cardiac output (CO, L/min) calculated as SV x heart 
rate. At the time of flow imaging, BP was simultaneously meas-
ured using MRI-compatible oscillometric sphygmomanometer 
(Datex Ohmeda). Systemic vascular resistance (SVR; measured 
in mmHg/L/min) was calculated by dividing the measured mean 
BP by CO. Total arterial compliance (TAC) was calculated by 
optimisation of the two-element Windkessel model. Briefly, the 
flow curves and SVR were used as inputs to the model. Pulse 
pressure (PP) was calculated for a series of modelled pres-
sure curves generated using a range of TAC values from 
0.1 to 5.0 mL/mmHg in increments of 0.01. The compliance 
value that gave the smallest error between the modelled PP 
and the true PP was taken to be the true compliance.
Dataset 5 – metabolic/metabolomic phenotypes
In order to assess cardiometabolic risk profiles, 15 ml of 
blood was collected at least 4–6 h post-meal using standard 
venepuncture techniques and divided between both serum and 
plasma (EDTA) vacutainers. Within 30 minutes of collection, 
samples were centrifuged for 12 mins at 4000 rpm, pipetted into 
1 ml Eppendorf tubes and immediately frozen at –80°C. 
Plasma lipids (total cholesterol, triglycerides, HDL choles-
terol, and direct LDL cholesterol), liver function tests (ALT, 
AST, and GGT), Apolipoprotein A1 and B, C-reactive protein, 
and glucose were measured using an automated analyser (c311, 
Roche Diagnostics, Burgess Hill, UK). Insulin was also measured 
using an automated immunoassay analyser (e411, Roche Diagnos-
tics, Burgess Hill, UK), while adiponectin, leptin and IL-6 (high 
sensitivity) were measured by ELISA (R&D systems, Abing-
don, UK). All measures were made using the manufacturer’s 
calibrators and quality control materials. Serum paraoxonase 
(PON-1) activities were measured by UV spectrophotom-
etry in a 96-well plate format using paraoxon (SigmaeAldrich, 
St Louis, Missouri). Metabolomic profiling was also performed 
on EDTA plasma samples by Nightingale Health (Finland) 
using a quantitative high-throughput NMR metabolomics 
platform, full details of which have been published elsewhere10.
Dataset 6 – psychological questionnaires
Three questionnaire-based psychological assessments were 
provided to participants on the day of testing in order to gauge 
indices of interpersonal support, happiness, and depression. The 
Interpersonal Support Evaluation List is a 12-item scale made 
up of three subscales – namely Tangible Support, Belonging 
Support, and Appraisal Support. All answers are given on a 
4-point scale ranging from ‘Definitely True’ to ‘Definitely 
False’ and participants are required to rate each statement depend-
ing on its relevance to them. For analysis, the scores for nega-
tively phrased statements are reversed and the scale totals for 
each subscale and the overall total are calculated10. The Oxford 
Happiness Questionnaire (OHQ) is a 29-item questionnaire; 
with each statement answered using a uniform 6-point Likert 
Scale. For analysis, negatively phrased questions are reversed 
and the sum total is divided by the number of questions to give 
an average score11. The Beck Depression Inventory II is a 
21-question multiple choice self-report inventory used to 
assess the severity of depression. Questions are scaled from 
0–3, with overall scores of 0–13 suggesting minimal depression, 
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Table 2. Participant characteristics dataset.
Variable Database ID n Mean (SD) or %
Age in years Age 436 21.0 (1.0)
Participant sex (M/F) Gender 436 34/66
Height in m Ht 436 1.71 (0.09)
Weight in kg Wt 436 72.2 (19.0)
Body mass index in kg/m2 Bmi 436 24.6 (5.7)
Waist circumference measured in cm Waistcirm 435 82.5 (13.7)
Hip circumference measured in cm Hipcircm 435 101.8 (11.5)
Sagittal-abdominal diameter measured in cm Sad 435 15.9 (48.9)
14–19 mild depression, 20–28 moderate depression, and 29–63 
severe depression12.
Ethical approval and consent
Ethical approval for the study was obtained from the ALSPAC 
Ethics and Law Committee and the Local Research Ethics Com-
mittees. Full details of the approvals obtained are available from 
the study website (http://www.bristol.ac.uk/alspac/researchers/
research-ethics/). Written informed consent was obtained from 
participants prior to their clinic visit. Study members have the 
right to withdraw their consent for elements of the study or from 
the study entirely at any time.
Data
For ease of navigation, results include only variables that are 
deemed to be of particular relevance to this study and have 
been separated into six distinct datasets contained within 
tables, namely Table 1, genetic risk groups; Table 2, participant 
characteristics; Table 3, adipose phenotypes; Table 4, cardio-
vascular phenotypes; Table 5, metabolic/metabolomic pheno-
types; and Table 6, psychological questionnaires. A selection of 
example graphs showing relationships between BMI and a number 
of these adipose, vascular, cardiac, and metabolic phenotypes 
can be found in the extended data8.
Table 1. Genetic risk groups dataset.
Variable Database ID n Mean (SD) or %
Genetic Risk Group 
(H/L) Genetic Group 419 54/46
Table 3. Adipose phenotypes dataset.
Variable Database ID n Mean (SD)
Sum of visceral fat Sumvf 409 20669 (20678)
Sum of subcutaneous fat Sumsq 409 177688 (95361)
Sum of body volume Sumbv 409 465622 (134155)
Number of voxels visceral fat Vfvoxel 409 2091 (2525)
Number of voxels subcutaneous fat Sqvoxel 411 17260 (9369)
Number of voxels total fat Tfvoxel 409 19362 (10778)
Number of voxels body volume Bvvoxel 409 43526 (15184)
Total body fat indexed to body volume Tfibv 409 0.384 (0.154)
Visceral fat indexed to body volume Vfibv 409 0.043 (0.036)
Subcutaneous fat indexed to body volume Sqibv 409 0.415 (0.198)
Total fat indexed to body surface area Tfibsa 409 10357 (4769)
Visceral fat indexed to body surface area Vfibsa 409 1089 (1147)
Subcutaneous fat indexed to body surface area Sqibsa 409 9310 (4189)
Subcutaneous fat indexed to visceral ratio Sqrvf 409 12.2 (7.9)
Mean absolute liver fat Livermean 412 184 (97)
Mean % liver fat Liverfatperc 412 4.5 (2.4)
Pericardial fat volume Pericardialvol 412 470 (411)
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Table 4. Cardiovascular phenotypes dataset.
Variable Database ID n Mean (SD)
Carotid Intima-Media Thickness
Mean right carotid artery diameter measured during diastole in mm Rbldc123 434 6.21 (0.47)
Mean right carotid artery diameter measured during peak systole in mm Rpkdc123 434 7.06 (0.53)
Mean right carotid artery far-wall IMT measured during diastole in mm Rblimt123 435 0.46 (0.05)
Mean right carotid artery far-wall IMT measured during peak-systole in mm Rpkimt123 433 0.44 (0.05)
Mean left carotid artery diameter measured during diastole in mm Lbldc123 435 6.25 (0.48)
Mean left carotid artery diameter measured during peak systole in mm Lpkdc123 435 7.04 (0.51)
Mean left carotid artery far-wall IMT measured during diastole in mm Lblimt123 435 0.46 (0.05)
Mean left carotid artery far-wall IMT measured during peak-systole in mm Lpkimt123 432 0.45 (0.05)
Pulse Wave Velocity
Carotid-Radial PWV in m/s Pwvrad 434 6.79 (0.93)
Carotid-Femoral PWV when distance measured via umbilicus in m/s Pwvfemviaub 419 5.59 (0.74)
Carotid-Femoral PWV when distance measured direct in m/s Pwvfemdirect 418 5.37 (0.70)
Flow-Mediated Dilation
Baseline brachial artery diameter in mm prior to cuff inflation Bldfmd 420 3.22 (0.52)
Peak percentage increase in arterial diameter following cuff deflation Pkfmdperc 418 8.2 (4.0)
Time in seconds (from start of baseline) to reach peak percentage 
increase in arterial diameter following cuff deflation Pkfmdtime 415 411 (17)
Mean baseline velocity-time integral in centimetres calculated from 
measurements 50, 30 and 10 seconds prior to cuff inflation Blvti123 427 0.07 (0.03)
Peak velocity-time integral in centimetres measured following cuff 
deflation Pkvti01 411 0.39 (0.11)
Peripheral Blood Pressure
Systolic blood pressure measured immediately prior to PWA using 
brachial cuff occlusion in mmHg Sbppwa 431 117 (10)
Diastolic blood pressure measured immediately prior to PWA using 
brachial cuff occlusion in mmHg Dbppwa 431 67 (7)
Pulse pressure calculated immediately prior to PWA as systolic blood 
pressure – diastolic blood pressure Pppwa 431 50 (10)
Mean arterial pressure calculated immediately prior to PWA as diastolic 
blood pressure + 1/3 (systolic blood pressure – diastolic blood pressure) Mappwa 431 84 (7)
Pulse Wave Analysis
Augmentation Pressure – extent to which central systolic pressure is 
augmented by the returning reflected pressure wave in mmHg Augment 430 -0.51 (3.49)
Augmentation index (expressed as a percentage) calculated by dividing 
augmentation pressure by pulse pressure Aiappp 430 -1.88 (10.38)
Augmentation index (expressed as a percentage) calculated by dividing 
pressure of the second peak observed within the central pressure 
waveform by the pressure of the first peak
Aip2p1 430 98.34 (11.14)
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Variable Database ID n Mean (SD)
Aortic systolic blood pressure estimated by PWA in mmHg Pwaasp 430 98 (8)
Aortic diastolic blood pressure estimated by PWA in mmHg Pwaadp 430 68 (7)
Aortic pulse pressure estimated by PWA in mmHg Pwaapp 430 30 (6)
Autonomic Function
BRS slope Brsslope 365 20.3 (9.6)
Time Domain Heart rate variability, SDNN Brstdhrv 357 73.3 (32.7)
Time Domain Heart rate variability, RMSSD Brstdhrv2 357 68.9 (45.8)
Time Domain Heart rate variability, Triangular Index Brstdhrv3 357 17.4 (6.1)
Ultra-High Frequency Ultrasound
50 MHz right radial artery diameter measured in mm vhrsrrad50mhz 175 1.86 (0.39)
50 MHz right radial artery intima-media thickness measured in mm vhrsrraimt50mhz 175 0.15 (0.03)
50 MHz right radial artery intima thickness measured in mm vhrsrrait50mhz 175 0.07 (0.01)
50 MHz right radial artery media thickness measured in mm vhrsrramt50mhz 175 0.09 (0.03)
50 MHz right dorsal paedal artery diameter measured in mm vhrsrdpad50mhz 145 1.31 (0.44)
50 MHz right dorsal paedal artery intima-media thickness measured in 
mm vhrsrdpaimt50mhz 145 0.17 (0.11)
50 MHz right dorsal paedal artery intima thickness measured in mm vhrsrdpait50mhz 145 0.07 (0.07)
50 MHz right dorsal paedal artery media thickness measured in mm vhrsrdpamt50mhz 145 0.10 (0.06)
Haemodynamic MRI Measures
Stroke volume in millilitres Mriao1sv 387 90 (17)
Cardiac output in litres Mriao1co 387 5.7 (1.2)
Systemic vascular resistance in mmHg/L/min Mriao1svr 387 15.6 (3.0)
Total arterial compliance in ml/mmHg Mriao1tac 387 1.02 (0.22)
Cardiac Structure MRI Measures
Left ventricular end diastolic volume in millilitres Mrilvedv 387 135 (27)
Left ventricular end systolic volume in millilitres Mrilvesv 387 46 (14)
Left ventricular stroke volume in millilitres Mrilvsv 387 89 (17)
Left ventricular ejection fraction (%) Mrilvef 387 66 (5)
Left ventricular mass Mrilvmass 387 91 (25)
Page 9 of 12
Wellcome Open Research 2018, 3:162 Last updated: 23 DEC 2018
Table 5. Metabolic/metabolomic phenotypes.
Variable Database ID n Mean (SD)
Apolipoprotein B measured in g/L ApoBgL 387 0.69 (0.23)
Apolipoprotein A measured in g/L ApoAgL 387 1.16 (0.29)
C-reactive protein measured in mg/L CRPmgL 366 2.00 (3.21)
Adiponectin measured in µg/L Adiponectinugml 386 27.1 (16.3)
Leptin measured in ng/mL Leptinngml 387 38.8 (36.2)
Interleukin-6 measured in pg/mL IL-6pgml 375 1.45 (1.23)
Glucose measured in mmol/L GlucosemmolL 385 3.75 (0.59)
Insulin measured in µU/mL InsulinuUml 385 8.9 (6.2)
Gamma-glutamyl transferase measured in U/L Ggtul 384 15.0 (14.8)
Alanine aminotransferase measured in U/L Altul 385 17.0 (11.6)
Aspartate aminotransferase measured in U/L Astul 384 24.8 (10.9)
Triglycerides measured in mmol/L TRIGmmolL 384 0.73 (0.32)
Total cholesterol measured in mmol/L CHOLmmolL 385 3.35 (1.01)
Low-density lipoprotein measured in mmol/L LDLmmolL 384 1.85 (0.73)
High-density lipoprotein measured in mmol/L HDLmmolL 384 1.03 (0.35)
Paraoxonase-1 Activity in µMol/P-Nitrophenol/
L/Serum/min PONActivityuMolPNitrophenol 304 877 (442)
Metabolomics See extended data
8 for complete list of all 
225 biomarkers measured using NMR 228-389 -
Table 6. Psychological questionnaires.
Variable Database ID n
Interpersonal Support Evaluation List
ISEL questions 1 – 12 as scored by participants Iselq1 – Iselq12 224
Scaled and reversed totals of questions 1 – 12 Iselscttl1 – Iselscttl12 224
Appraisal subscale – calculated from total 
combined score of questions 2, 4, 6 and 11. Iselappsubs 224
Belonging subscale – calculated from total 
combined score of questions 1, 5, 7 and 9. Iselbelsubsc 224
Tangible subscale – calculated from total 
combined score of questions 3, 8, 10 and 12. Iseltangsubs 224
Oxford Happiness Questionnaire
OHQ questions 1 – 29 as score by participants Oxhqa1 – Oxhqa29 224
Converted totals for negatively phrased questions Oxhct1 – Oxhct29 224
Sum of converted totals Oxhsumct 224
Final score Oxhscore 224
Beck Depression Inventory II
BDI-II questions 1 – 21 as scored by participant Prsonqa1 – Prsonqa21 224
Final Score Prsonscore 224
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Dataset validation
In order to minimise variability inherent in the assessment of 
certain vascular phenotypes (e.g. carotid intima-media thickness, 
pulse-wave velocity, flow-mediated dilation), all study techni-
cians working on the study were required to undergo identical 
training and accreditation procedures as those conducted in pre-
vious ALSPAC vascular clinics prior to scanning participants, 
details of which have been published elsewhere13,14. All blood 
samples were analysed in a single batch upon completion of the 
study in order to minimise any potential inter-assay variability. As 
with all large-scale studies, a number of variables have differ-
ent degrees of missing data. Information on the extent of missing 
data for each variable can be found within each of the descrip-
tive tables provided within this data note. Of note, around 10% 
of participants refused to provide a blood sample due to fear of 
needles. In addition, ultra-high frequency resolution ultrasound 
and psychological questionnaires were only added to the main 
study protocol in 2013, and data for these variables are 
therefore available in only a sub-sample of participants.
Data availability
Underlying data
ALSPAC data access is through a system of managed open 
access. Full details of all available data can be accessed through 
a fully searchable data dictionary provided on the ALSPAC 
study website (http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary) and the steps below highlight how to 
apply for access to both the data included in this data note and 
all other ALSPAC data. The datasets presented in this data note 
are linked to ALSPAC project number B645; please quote this 
project number during your application. The ALSPAC vari-
able codes highlighted in the dataset descriptions can be used to 
specify required variables.
1.    Please read the ALSPAC access policy (PDF, 627kB) which 
describes the process of accessing the data and samples in 
detail and outlines the costs associated with doing so.
2.    You may also find it useful to browse our fully search-
able research proposals database, which lists all research 
projects that have been approved since April 2011.
3.    Please submit your research proposal for consideration 
by the ALSPAC Executive Committee using the online 
process. You will receive a response within 10 work-
ing days to advise you whether your proposal has been 
approved.
If you have any questions about accessing data, please email 
alspac-data@bristol.ac.uk.
The ALSPAC data management plan describes in detail the 
policy regarding data sharing, which is through a system of 
managed open access.
Extended data
Extended data, including example graphs showing relationships 
between BMI and other phenotypes, descriptive metabolomics 
data and the ALSPAC in London medical history question-
naire, can be found in the figshare data repository. DOI: https:// 
doi.org/10.6084/m9.figshare.c.4337849.v18.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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